Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. | Journal of Psychopharmacology | 25 June 2018
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. | Frontiers in Pharmacology | 5 June 2018
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens, P., & Atherton, W. L. | Journal of Psychedelic Studies | 30 May 2018
Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Cata-Preta, E. G., Serra, Y. A., Moreira-Junior, E. D. C., Reis, H. S., Kisaki, N. D., Libarino-Santos, M., ... & Costa, J. L. | Frontiers in pharmacology | 29 May 2018
The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine
Malcolm, B. J., Polanco, M., & Barsuglia, J. P. | Journal of psychoactive drugs | 2 April 2018
Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study
Dorsen, C., Palamar, J., & Shedlin, M. G. | Addiction Research & Theory | 30 March 2018
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. | Frontiers in Pharmacology | 21 February 2018
Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., ... & Mennenga, S. E. | Frontiers in Pharmacology | 20 February 2018
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation
Curran, H. V., Nutt, D., & de Wit, H. | Psychopharmacology | 14 February 2018
The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes
Oreščanin-Dušić, Z., Tatalović, N., Vidonja-Uzelac, T., Nestorov, J., Nikolić-Kokić, A., Mijušković, A., ... & Blagojević, D. | Oxidative medicine and cellular longevity | 11 February 2018
Evaluating the abuse potential of psychedelic drugs for medical use in humans
Heal, D. J., Gosden, J., & Smith, S. L. | Neuropharmacology | 7 February 2018
Ayahuasca: Psychological And Physiologic Effects, Pharmacology And Potential Uses In Addiction And Mental Illness
Hamill, J., Hallak, J., Dursun, S. M., & Baker, G. | Current neuropharmacology | 24 January 2018
Ketamine for the treatment of addiction: Evidence and potential mechanisms
Ezquerra-Romano, I. I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. | Neuropharmacology | 12 January 2018
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study
Dakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. | Neuropharmacology | 5 January 2018
Breaking the cycle of opioid use disorder with Ibogaine
C. Mash, D. | The American Journal of Drug and Alcohol Abuse | 7 December 2017
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
Fattore, L., Piva, A., Zanda, M. T., Fumagalli, G., & Chiamulera, C. | Psychopharmacology | 25 November 2017
Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
Lawn, W., Hallak, J. E., Crippa, J. A., Santos, R., Porffy, L., Barratt, M. J., ... & Morgan, C. J. | Scientific reports | 9 November 2017
Why MDMA therapy for alcohol use disorder? And why now?
Sessa, B. | Neuropharmacology | 7 November 2017
Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning
Davis, A. K., Barsuglia, J. P., Windham-Herman, A. M., Lynch, M., & Polanco, M. | Journal of Psychedelic Studies | 17 October 2017
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. | Trends in Pharmacological Sciences | 22 September 2017
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. | BMJ open | 21 September 2017
A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment
Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M., Tófoli, L. F., Chaves, B. D. R., & da Silveira, D. X. | Journal of Psychedelic Studies | 29 August 2017
Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges
Majić, T., Jungaberle, H., Schmidt, T. T., Zeuch, A., Hermle, L., & Gallinat, J. | Fortschritte der Neurologie-Psychiatrie | 2 August 2017
The 2017 Ayahuasca Technical Report
ICEERS has just released the 2017 edition of the Ayahuasca Technical Report. Signed by ten of the world’s leading ayahuasca researchers, this report is an important document that summarizes the most relevant scientific findings from [...]